Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained...
The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study...
The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
COYA 303 is an investigational proprietary biologic combination of low-dose (LD)-IL-2 and GLP-1 receptor agonist (RA) for subcutaneous administration with potential for treating inflammation-driven diseases...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...
Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs)...